RecruitingPHASE1, PHASE2NCT06484829

Purinostat Mesylate Combined With Pomalidomide Capsules and Low-dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

Studying Cap myopathy

Last synced from ClinicalTrials.gov

ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing data

Key facts

Sponsor
Chengdu Zenitar Biomedical Technology Co., Ltd
Principal Investigator
Ting Niu, Doctor
West China Hospital
Intervention
Purinostat Mesylate 4 mg/m2(drug)
Enrollment
144 target
Eligibility
18-75 years · All sexes
Timeline
2024 – 2026

Study locations (1)

Primary source

Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.

Open NCT06484829 on ClinicalTrials.gov

Other trials for Cap myopathy

Additional recruiting or active studies for the same condition.

See all trials for Cap myopathy →

← Back to all trials